Compare · BEN vs HQL
BEN vs HQL
Side-by-side comparison of Franklin Resources Inc. (BEN) and abrdn Life Sciences Investors Shares of Beneficial Interest (HQL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BEN and HQL operate in Investment Managers (Finance), so they compete in similar markets.
- BEN is the larger of the two at $16.31B, about 38.1x HQL ($428.1M).
- Over the past year, BEN is up 43.5% and HQL is up 29.8% - BEN leads by 13.8 points.
- BEN has been more active in the news (10 items in the past 4 weeks vs 2 for HQL).
- BEN has more recent analyst coverage (24 ratings vs 0 for HQL).
- Company
- Franklin Resources Inc.
- abrdn Life Sciences Investors Shares of Beneficial Interest
- Price
- $31.38+0.18%
- $16.65-1.39%
- Market cap
- $16.31B
- $428.1M
- 1M return
- +2.78%
- -7.24%
- 1Y return
- +43.55%
- +29.77%
- Industry
- Investment Managers
- Investment Managers
- Exchange
- NYSE
- NYSE
- IPO
- 1992
- News (4w)
- 10
- 2
- Recent ratings
- 24
- 0
Franklin Resources Inc.
Franklin Resources, Inc. is a publicly owned asset management holding company. Through its subsidiaries, the firm provides its services to individuals, institutions, pension plans, trusts, and partnerships. It launches equity, fixed income, balanced, and multi-asset mutual funds through its subsidiaries. The firm invests in the public equity, fixed income, and alternative markets. Franklin Resources, Inc. was founded in 1947 and is based in San Mateo, California with an additional office in Hyderabad, India.
abrdn Life Sciences Investors Shares of Beneficial Interest
Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.
Latest BEN
- Franklin Resources Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Franklin Templeton Launches YCLO, an Actively Managed Investment Grade CLO ETF
- Fiduciary Trust International Welcomes Harrison Laing as New York-Based Wealth Director
- Franklin Resources, Inc. Announces Preliminary Month-End Assets Under Management
- Amendment: SEC Form 40-6B/A filed by Franklin Resources Inc.
- Franklin Templeton and MoonPay Partner to Expand Institutional Access to Tokenized Money Market Funds
- Franklin Templeton Canada Announces ETF Cash Distributions
- Franklin Resources, Inc. Announces Quarterly Dividend
- Franklin Templeton Canada Announces Final Valuations for Terminated ETF Series
- Clarion Partners Executes $1 Billion in Strategic Healthcare Real Estate Transactions Across Multiple High-Growth Markets
Latest HQL
- SEC Form N-CSRS filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- ABERDEEN INVESTMENTS U.S. CLOSED-END FUNDS ANNOUNCE RESULTS OF ANNUAL MEETING OF SHAREHOLDERS
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- Certain Aberdeen Investments U.S. Closed-End Funds Declare Distribution Dates and Amounts
- Aberdeen Investments U.S. Closed-End Funds Announce Distribution Payment Details
- SEC Form 3 filed by new insider Reilly Heather Carter
- Director Pittard Christian bought $133,755 worth of shares (7,923 units at $16.88) (SEC Form 4)
- SEC Form N-CSR filed by abrdn Life Sciences Investors Shares of Beneficial Interest
- SEC Form N-CEN filed by abrdn Life Sciences Investors Shares of Beneficial Interest